<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) in first complete remission for patients who are NOT eligible for hematopoietic cell transplantation (HCT)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) in first complete remission for patients who are NOT eligible for hematopoietic cell transplantation (HCT)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Management of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) in first complete remission for patients who are NOT eligible for hematopoietic cell transplantation (HCT)</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">This algorithm should be used in conjunction with related UpToDate content regarding transplant eligibility, detection of MRD, maintenance therapy, and related material.</div><div class="graphic_footnotes">Ph+ ALL: Philadelphia chromosome positive acute lymphoblastic leukemia; CR: hematologic complete remission; MRD: measurable residual disease based on quantitative reverse transcriptase polymerase chain reaction for <em>BCR-ABL1</em>; HCT: hematopoietic cell transplantation; TKI: BCR-ABL1 tyrosine kinase inhibitor.<br/>* MRD detectable in bone marrow: &lt;MR4.5 (<em>BCR-ABL1</em> &gt;10<sup>–4.5)</sup>.<br/>¶ TKI should be held during blinatumomab treatment and resumed for maintenance therapy.</div><div id="graphicVersion">Graphic 130442 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
